Beta Drugs Limited

Some notes on Beta Drugs:

BETADR derived ( Sep 2023)

~30% of revenue from branded products;

48% from contract manufacturing for leading companies like Hetero Drugs, Cadila Pharmaceuticals, Alkem Laboratories, Shilpa Medicare, RPG Life Sciences, and Glenmark Pharmaceuticals;

13% from exports;

8% from APIs; and

1% from the recently launched dermatology and cosmetology divisions.

The dermatology/cosmetology segment is expected to break even in H2FY24.

Exports:

Though export revenue clocked 44% CAGR over FY19–23, it remains in the nascent phase (contributed ~12% in FY23).

BETADR currently derives ~8% revenue from the API segment, The company derived ~28% of revenue from exports in FY23.

CDMO Segment:
The CDMO segment accounted for 48% of revenue in FY23 and clocked 20% CAGR over FY19–23. Over the years, it has developed strong partnerships with its partners. BETADR has more than 50 customers in the CDMO segment. Some of its marquee clients are Intas Pharmaceuticals, Glenmark Pharmaceuticals, Reliance Life Sciences Pvt.

New Business: dermatology and cosmetology
The company recognised a revenue of INR3.9cr from this segment in FY23 with 12 products as of now.
Plans:

1. plans to launch five products each in FY24 and FY25 and seven products in FY26 including four-to-five NDDS.